Cetuximab: its unique place in head and neck cancer treatment

References

• ForastiereAKochWTrottiASidranskyDHead and neck cancerN Engl J Med2001345261890190011756581
   PubMed Web of Science ®Google Scholar
• The Globocan Project [website on the Internet]GenevaWorld Health Organization2010 Available from: http://globocan.iarc.fr/Accessed January 27, 2013
   Google Scholar
• Head and Neck Cancers [website on the Internet]BethesdaNational Institutes of Health2013 Available from: http://www.cancer.gov/cancertopics/factsheet/sites-types/head-and-neckAccessed January 27, 2013
   Google Scholar
• MarurSD’SouzaGWestraWHForastiereAAHPV-associated head and neck cancer: a virus-related cancer epidemicLancet Oncol201011878178920451455
   PubMed Web of Science ®Google Scholar
• NäsmanAAttnerPHammarstedtLIncidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?Int J Cancer2009125236236619330833
   PubMed Web of Science ®Google Scholar
• AttnerPNäsmanADuJSurvival in patients with human papillomavirus positive tonsillar cancer in relation to treatmentInt J Cancer201213151124113022038860
   PubMed Web of Science ®Google Scholar
• AttnerPDuJNäsmanAHuman papillomavirus and survival in patients with base of tongue cancerInt J Cancer2011128122892289720725995
   PubMed Web of Science ®Google Scholar
• HaddadRIShinDMRecent advances in head and neck cancerN Engl J Med2008359111143115418784104
   PubMed Web of Science ®Google Scholar
• AngKKMultidisciplinary management of locally advanced SCCHN: optimizing treatment outcomesOncologist200813889991018701764
   PubMed Web of Science ®Google Scholar
• GrégoireVLefebvreJLLicitraLFelipEEHNS-ESMO-ESTRO Guidelines Working GroupSquamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201021Suppl 5v184v18620555077
   PubMed Web of Science ®Google Scholar
• SpecenierPMVermorkenJBRecurrent head and neck cancer: current treatment and future prospectsExpert Rev Anticancer Ther20088337539118366286
   PubMed Web of Science ®Google Scholar
• GrandisJREstablished and emerging concepts in epidermal growth factor receptor biologyInt J Radiat Oncol Biol Phys200769Suppl 2S22S2417848285
   PubMed Web of Science ®Google Scholar
• GrandisJRTweardyDJElevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancerCancer Res19935315357935848339264
   PubMed Web of Science ®Google Scholar
• DassonvilleOFormentoJLFrancoualMExpression of epidermal growth factor receptor and survival in upper aerodigestive tract cancerJ Clin Oncol19931110187318788410112
   PubMed Web of Science ®Google Scholar
• AngKKAndratschkeNHMilasLEpidermal growth factor receptor and response of head-and-neck carcinoma to therapyInt J Radiat Oncol Biol Phys200458395996514967456
   PubMed Web of Science ®Google Scholar
• SpecenierPVermorkenJBBiologic therapy in head and neck cancer: a road with hurdlesISRN Oncol2012201216375222745915
   PubMedGoogle Scholar
• SpecenierPMVermorkenJBTargeted therapies in head and neck cancerTarget Oncol2007227388
   Web of Science ®Google Scholar
• SpecenierPVermorkenJBCetuximab in the treatment of squamous cell carcinoma of the head and neckExpert Rev Anticancer Ther201111451152421504318
   PubMed Web of Science ®Google Scholar
• HuangSMBockJMHarariPMEpidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neckCancer Res19995981935194010213503
   PubMed Web of Science ®Google Scholar
• SalehMNRaischKPStackhouseMACombined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiationCancer Biother Radiopharm199914645146310850332
   PubMed Web of Science ®Google Scholar
• ZhangNErjalaKKulmalaJConcurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitroRadiother Oncol200992338839219447510
   PubMed Web of Science ®Google Scholar
• FanZBaselgaJMasuiHMendelsohnJAntitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenograftsCancer Res19935319463746428402640
   PubMed Web of Science ®Google Scholar
• DirksNLNoltingAKovarAMeibohmBPopulation pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neckJ Clin Pharmacol200848326727818218786
   PubMed Web of Science ®Google Scholar
• BaselgaJPfisterDCooperMRPhase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatinJ Clin Oncol200018490491410673534
   PubMed Web of Science ®Google Scholar
• ShinDMDonatoNJPerez-SolerREpidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancerClin Cancer Res2001751204121311350885
   PubMed Web of Science ®Google Scholar
• RobertFEzekielMPSpencerSAPhase I study of anti – epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancerJ Clin Oncol200119133234324311432891
   PubMed Web of Science ®Google Scholar
• BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckN Engl J Med2006354656757816467544
   PubMed Web of Science ®Google Scholar
• BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalLancet Oncol2010111212819897418
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyErbitux: EPAR – Product InformationLondonEuropean Medicines Agency2009 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000558/WC500029119.pdfAccessed January 27, 2013
   Google Scholar
• US Food and Drug AdministrationSilver Spring: US Food and Drug Administration Available from: http://www.accessdata.fda.gov/drugsatfda_docs//label/2004/125084lbl.pdfAccessed January 27, 2013
   Google Scholar
• PignonJPle MaîtreAMaillardEBourhisJMACH-NC Collaborative GroupMeta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patientsRadiother Oncol200992141419446902
   PubMed Web of Science ®Google Scholar
• KoutcherLShermanEFuryMConcurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancerInt J Radiat Oncol Biol Phys201181491592220947269
   PubMed Web of Science ®Google Scholar
• WalshLGillhamCDunneMToxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC)Radiother Oncol2011981384121159400
   PubMed Web of Science ®Google Scholar
• ChewAHayJLaskinJJWuJHoCToxicity in combined modality treatment of HNSCC: Cisplatin versus cetuximabJ Clin Oncol201129Suppl Abstr 5526
   Google Scholar
• ShapiroLQShermanEJKoutcherLEfficacy of concurrent cetuximab (C225) versus 5-fluorouracil/carboplatin (5FU/CBDCA) or cisplatin (CDDP) with intensity-modulated radiation therapy (IMRT) for locally advanced head and neck cancer (LAHNSCC)J Clin Oncol201230Suppl Abstr 5537
   Google Scholar
• PryorDIPorcedduSVBurmeisterBHEnhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancerRadiother Oncol200990217217618976827
   PubMed Web of Science ®Google Scholar
• KaoJGendenEMGuptaVPhase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancerCancer2011117231832620830768
   PubMed Web of Science ®Google Scholar
• MerlanoMOccelliMReview of cetuximab in the treatment of squamous cell carcinoma of the head and neckTher Clin Risk Manag20073587187618473010
   PubMedGoogle Scholar
• SeiwertTYHarafDJCohenEEA randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC)J Clin Oncol201129Suppl Abstr 5519
   Google Scholar
• SuntharalingamMKwokYGoloubevaOPhase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neckInt J Radiat Oncol Biol Phys20128251845185021601372
   PubMed Web of Science ®Google Scholar
• TongCCLauKHRiveraMPrognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapyOncol Rep20122751580158622322320
   PubMed Web of Science ®Google Scholar
• MerlanoMRussiEBenassoMCisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical studyAnn Oncol201122371271720810547
   PubMed Web of Science ®Google Scholar
• ArgirisAKaramouzisMVSmithRPhase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancerAnn Oncol201122112482248821363880
   PubMed Web of Science ®Google Scholar
• LicitraLBergaminiCOlmiPSoldatenkovaVAmeryckxSRussoFPhase I study of concurrent pemetrexed, cetuximab and radiation therapy with or without cisplatin in patients with locally advanced squamous cell carcinoma of the head and neckAnn Oncol201021Suppl 81025
   Google Scholar
• AngKKZhangQRosenthalDIA randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC)J Clin Oncol201129Suppl Abstr 5500
   Google Scholar
• MesíaRRuedaAVeraRAdjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trialAnn Oncol201324244845323041591
   PubMed Web of Science ®Google Scholar
• BrizelDMVokesEEInduction chemotherapy: to use or not to use? That is the questionSemin Radiat Oncol2009191111619028340
   PubMed Web of Science ®Google Scholar
• PointreauYAteanIFayetteJCalaisGLefebvreJLInduction chemotherapy in head and neck cancer: a new paradigmAnticancer Drugs201122761362021160420
   PubMed Web of Science ®Google Scholar
• SpecenierPMVermorkenJBNeoadjuvant chemotherapy in head and neck cancer: should it be revisited?Cancer Lett2007256216617717673364
   PubMed Web of Science ®Google Scholar
• VokesEEInduction chemotherapy for head and neck cancer: recent dataOncologist201015Suppl 33721036882
   PubMed Web of Science ®Google Scholar
• ArgirisAHeronDESmithRPInduction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancerJ Clin Oncol201028365294530021079141
   PubMed Web of Science ®Google Scholar
• KiesMSHolsingerFCLeeJJInduction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trialJ Clin Oncol201028181419917840
   PubMed Web of Science ®Google Scholar
• WaneboHGhebremichaelMSBurtnessBPhase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68–72 Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG E2303)J Clin Oncol20102815s Abstr 5513
   Google Scholar
• AdkinsDLeyJTrinkausKA phase 2 trial of induction nab- paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neckCancer2013119476677322991252
   PubMed Web of Science ®Google Scholar
• VermorkenJBRemenarEvan den WeyngaertDFeasibility of cetuximab plus sequential platinum-based therapy (TPF/CRT) in advanced squamous cell head and neck cancer (SCCHN): a randomized phase II study of the EORTC Head and Neck Cancer GroupEur Arch Otorhinolaryngol201226913111410 OP 42 (Abstract)
   Google Scholar
• HaddadRITishlerRBNorrisCPhase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neckJ Clin Oncol200927274448445319704061
   PubMed Web of Science ®Google Scholar
• JordanWWildfangIWelkoborskyHTPF induction-radioimmunochemotherapy for the treatment of advanced head and neck cancerJ Clin Oncol20102815s Abstr 5514
   Google Scholar
• GhiMGPaccagnellaAFerrariDCetuximab/radiotherapy (CET+RT) versus concomitant chemoradiotherapy (cCHT+RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Preliminary results on toxicity of a randomized, 2 × 2 factorial, phase II–III study (NCT01086826)J Clin Oncol201230Suppl Abstr 5513
   Google Scholar
• LefebvreJLPointreauYRollandFInduction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized Phase II studyJ Clin Oncol20133185385923341517
   PubMed Web of Science ®Google Scholar
• KeilFSelzerEBergholdAInduction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neckEur J Cancer201349235235922981499
   PubMed Web of Science ®Google Scholar
• AkmansuMBuyukberberSIrenSCetuximab concomitant with second-line radiation therapy in patients with locally advanced recurrent squamous cell head and neck cancerCase Rep Oncol20103348048821611102
   PubMedGoogle Scholar
• BalermpasPHambekMSeitzORödelCWeissCCombined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neckStrahlenther Onkol20091851277578120013086
   PubMed Web of Science ®Google Scholar
• CometBKramarAFaivre-PierretMSalvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility studyInt J Radiat Oncol Biol Phys201284120320922331006
   PubMed Web of Science ®Google Scholar
• ZwickerFRoederFThiekeCIMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancerStrahlenther Onkol20111871323821234529
   PubMed Web of Science ®Google Scholar
• HeronDERwigemaJCGibsonMKBurtonSAQuinnAEFerrisRLConcurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control studyAm J Clin Oncol201134216517220686406
   PubMed Web of Science ®Google Scholar
• KiesMSHarrisJRotmanMZPhase II randomized trial of postoperative chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234)Int J Radiat Oncol Biol Phys2009753S14S15
   Web of Science ®Google Scholar
• BurtnessBGoldwasserMAFloodWMattarBForastiereAAEastern Cooperative Oncology GroupPhase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group studyJ Clin Oncol200523248646865416314626
   PubMed Web of Science ®Google Scholar
• VermorkenJBMesiaRRiveraFPlatinum-based chemotherapy plus cetuximab in head and neck cancerN Engl J Med2008359111116112718784101
   PubMed Web of Science ®Google Scholar
• LicitraLMesiaRRiveraFEvaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME studyAnn Oncol20112251078108721048039
   PubMed Web of Science ®Google Scholar
• SpecenierPVermorkenJBThe role of taxanes and targeted therapies in locally advanced head and neck cancerCurr Opin Oncol200719319520117414636
   PubMed Web of Science ®Google Scholar
• HittRIrigoyenACortes-FunesHGrauJJGarcía-SáenzJACruz-HernandezJJSpanish Head and Neck Cancer Cooperative Group (TTCC)Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neckAnn Oncol20122341016102221865152
   PubMed Web of Science ®Google Scholar
• GuigayJFayetteJDilliesAFCetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008–2003J Clin Oncol201129Suppl Abstr 5567
   Google Scholar
• ClarkJIGreeneJBLau ClarkADalalJSHofmeisterCCPhase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancerMed Oncol201330135823266940
   PubMed Web of Science ®Google Scholar
• VermorkenJBGaulerTCStoehlmacher-WilliamsJPhase II study of pemetrexed plus cisplatin and cetuximab in advanced squamous cell carcinoma of the head and neckAnn Oncol201223ix334ix347 1022PD (Abstract)
   Web of Science ®Google Scholar
• BaselgaJTrigoJMBourhisJPhase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neckJ Clin Oncol200523245568557716009950
   PubMed Web of Science ®Google Scholar
• HerbstRSArquetteMShinDMPhase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neckJ Clin Oncol200523245578558716009949
   PubMed Web of Science ®Google Scholar
• VermorkenJBTrigoJHittROpen-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapyJ Clin Oncol200725162171217717538161
   PubMed Web of Science ®Google Scholar
• VermorkenJBHerbstRSLeonXAmellalNBaselgaJOverview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapiesCancer2008112122710271918481809
   PubMed Web of Science ®Google Scholar
• LeónXHittRConstenlaMA retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapyClin Oncol (R Coll Radiol)200517641842416149284
   PubMed Web of Science ®Google Scholar
• FuryMGShermanELisaDA randomized phase ii study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancerJ Natl Compr Canc Netw201210111391139823138167
   PubMed Web of Science ®Google Scholar
• MassaEDessìMGaspardiniGSabaFCherchiVMantovaniGPhase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimensOral Oncol2010461181882120920877
   PubMed Web of Science ®Google Scholar
• KnoedlerMKGaulerTMatzdorffAMulticenter phase II study of cetuximab plus docetaxel in 84 patients with recurrent or metastatic, platinum-pretreated SCCHNJ Clin Oncol20092715s Abstr 6048
   Google Scholar
• TinhoferIKlinghammerKWeichertWExpression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatmentClin Cancer Res201117155197520421653686
   PubMed Web of Science ®Google Scholar
• ArgirisADuffyAGKummarSEarly tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancerClin Cancer Res201117175755576421750205
   PubMed Web of Science ®Google Scholar
• ArgirisAKotsakisAPHoangTCetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neckAnn Oncol201324122022522898037
   PubMed Web of Science ®Google Scholar
• StatBite: Radiation therapy plus cetuximab: skin reactions from 71 head and neck cancer patients from 11 institutions in EuropeJ Natl Cancer Inst201010227520054017
   PubMedGoogle Scholar
• AzadASevere cutaneous toxicity following treatment with radiotherapy and cetuximab: a case reportCases J2009212519128507
   PubMedGoogle Scholar
• BillanSAbdah-BortnyakRKutenASevere desquamation with skin necrosis: a distinct pattern of skin toxicity secondary to head and neck irradiation with concomitant cetuximabIsr Med Assoc J200810324718494248
   PubMed Web of Science ®Google Scholar
• BölkeEGerberPALammeringGDevelopment and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximabStrahlenther Onkol2008184210511018259703
   PubMed Web of Science ®Google Scholar
• BudachWBölkeEHomeyBSevere cutaneous reaction during radiation therapy with concurrent cetuximabN Engl J Med2007357551451517671265
   PubMed Web of Science ®Google Scholar
• ChanATeohDSangheraPHartleyARadiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancerRadiother Oncol200993365419524312
   PubMed Web of Science ®Google Scholar
• GiroCBergerBBölkeEHigh rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutesRadiother Oncol200990216617118977050
   PubMed Web of Science ®Google Scholar
• KoutcherLDWoldenSLeeNSevere radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximabAm J Clin Oncol200932547247619487913
   PubMed Web of Science ®Google Scholar
• MydinARArmstrongJGAcneiform rash secondary to cetuximab plus head and neck radiotherapyRadiother Oncol200785117117531339
   PubMed Web of Science ®Google Scholar
• StuderGBrownMSalgueiroEBGrade 3/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRTInt J Radiat Oncol Biol Phys201181111011720732757
   PubMed Web of Science ®Google Scholar
• Vano-GalvanSde las HerasEHartoAJaenPSevere cutaneous toxicity during concomitant radiotherapy and cetuximab treatment of head and neck cancerEur J Dermatol200818447147218573734
   PubMed Web of Science ®Google Scholar
• WarisWNaikSIdreesISevere cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancerCutan Ocul Toxicol2009281414419514925
   PubMed Web of Science ®Google Scholar
• LangendijkJAOostingSFGrading system and management guidelines for dermatitis induced by head and neck radiotherapy plus cetuximab: clinical validation requiredAnn Oncol201122102157215921878428
   PubMed Web of Science ®Google Scholar
• BernierJBonnerJVermorkenJBConsensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neckAnn Oncol200819114214917785763
   PubMed Web of Science ®Google Scholar
• BernierJRussiEGHomeyBManagement of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelinesAnn Oncol201122102191220021606209
   PubMed Web of Science ®Google Scholar
• GrandvuilleminADisson-DautricheAMiremont-SalaméGFourrier-ReglatASgroCThe Reseau des Centres Regionaux de Pharmacovigilance FrancaisCetuximab infusion reactions: French pharmacovigilance database analysisJ Oncol Pharm Pract Epub November 15, 2012
   Google Scholar
• HansenNLChandiramaniDVMorseMAWeiDHedrickNEHansenRAIncidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical centerJ Oncol Pharm Pract201117212513020147576
   PubMedGoogle Scholar
• MesíaRRiveraFKaweckiAQuality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neckAnn Oncol201021101967197320335368
   PubMed Web of Science ®Google Scholar
• CurranDGiraltJHarariPMQuality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximabJ Clin Oncol200725162191219717538164
   PubMed Web of Science ®Google Scholar
• GriffinSWalkerSSculpherMCetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neckHealth Technol Assess200913Suppl 1495419567214
   PubMed Web of Science ®Google Scholar
• BrownBDiamantopoulosABernierJAn economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United KingdomValue Health200811579179918194407
   PubMed Web of Science ®Google Scholar
• ChanALLeungHWHuangSFCost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan: a decision-tree analysisClin Drug Investig20113110717726
   Web of Science ®Google Scholar
• GreenhalghJBagustABolandACetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neckHealth Technol Assess200913Suppl 3495419846029
   PubMed Web of Science ®Google Scholar
• HannoufMBSehgalCCaoJQMocanuJDWinquistEZaricGSCost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancerPLoS One201276e3855722745668
   PubMed Web of Science ®Google Scholar